Dr. Feinstein - Key Opinion Leader in Research and Development
Piedmont Cancer Institute Dr. Trevor Feinstein presented to a global audience on June 25, 2021, concerning unmet medical need in treating patients with non-small cell lung cancer (NSCLC) and patients who failed checkpoint inhibitors. Dr. Feinstein joined Steven Lin, M.D. from M.D. Anderson in discussing the current treatment landscape of non-small cell lung cancer and the need for to think outside the box.
Dr. Feinstein’s talk provided an update on plinabulin’s data in NSCLC. He is the principal investigator of the DUBLIN-3 trial with studied Plinabulin in advanced NSCLC as second- or third-line therapy. Dr. Feinstein indicated the hour-long virtual conference was a success and many questions were asked regarding the progress to combat lung cancer. Dr. Assikis, the Director of Research at Piedmont Cancer Institute, says that "We are very proud of Dr. Feinstein’s hard work and dedication in the field of research. I have never seen someone so committed to helping patients throughout the metro Atlanta areas by providing excellent cancer care. It is our mission to exceed conventional understanding and treatment methodology of cancer by using the most advanced, personalized therapies available - always putting the patient first."
Dr. Feinstein is the recipient of numerous honors and awards. Dr. Feinstein is a Diplomate of the American Board of Medical Oncology and the American Board of Hematology. He holds memberships with the American Society of Clinical Oncology and Georgia Society of Clinical Oncology.
Dr. Feinstein is located in our Fayetteville office and appointments are available by calling 678-829-1060.